1. Home
  2. NWS vs RPRX Comparison

NWS vs RPRX Comparison

Compare NWS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo News Corporation Class B

NWS

News Corporation Class B

HOLD

Current Price

$27.02

Market Cap

17.0B

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$45.60

Market Cap

19.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWS
RPRX
Founded
2012
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0B
19.4B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NWS
RPRX
Price
$27.02
$45.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$37.94
$47.75
AVG Volume (30 Days)
1.6M
3.4M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
0.75%
1.98%
EPS Growth
N/A
N/A
EPS
N/A
1.78
Revenue
N/A
$2,378,193,000.00
Revenue This Year
$6.06
$38.30
Revenue Next Year
$3.25
$4.80
P/E Ratio
$12.98
$26.64
Revenue Growth
N/A
5.06
52 Week Low
$25.49
$29.66
52 Week High
$35.58
$47.86

Technical Indicators

Market Signals
Indicator
NWS
RPRX
Relative Strength Index (RSI) 46.97 57.40
Support Level $25.55 $35.32
Resistance Level $30.26 $46.14
Average True Range (ATR) 0.59 0.93
MACD 0.18 -0.03
Stochastic Oscillator 89.70 26.06

Price Performance

Historical Comparison
NWS
RPRX

About NWS News Corporation Class B

News Corporation is a diversified media conglomerate with large presence in the US, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. Its 61%-owned REA Group is the dominant property listings platform in Australia. In addition, it owns Harper Collins, one of the largest book publishers in the world, and has a sizable US digital property advertising business, Move. The 65% interest in Foxtel, the Australian pay-TV and streaming provider, was sold in April 2025. The sale to global sports streaming platform, DAZN, was struck at more than 7 times Foxtel's EBITDA.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: